Provided by Tiger Fintech (Singapore) Pte. Ltd.

Entera Bio Ltd.

2.51
+0.340015.67%
Post-market: 2.47-0.0400-1.59%19:57 EDT
Volume:625.42K
Turnover:1.51M
Market Cap:114.62M
PE:-9.89
High:2.55
Open:2.18
Low:2.15
Close:2.17
52wk High:2.79
52wk Low:1.50
Shares:45.66M
Float Shares:28.77M
Volume Ratio:7.48
T/O Rate:2.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2538
EPS(LYR):-0.2534
ROE:-82.22%
ROA:-44.56%
PB:6.64
PE(LYR):-9.90

Loading ...

Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress

GlobeNewswire
·
Sep 15

Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025

GlobeNewswire
·
Sep 08

Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences

GlobeNewswire
·
Aug 28

Entera Bio Q2 EPS $(0.06) Misses $1.21 Estimate

Benzinga
·
Aug 09

Entera Bio Reports Q2 2025 Net Loss of $2.7M, EPS Unchanged at $0.06

Reuters
·
Aug 09

Press Release: Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

Dow Jones
·
Aug 09

Entera Bio Ltd expected to post a loss of 11 cents a share - Earnings Preview

Reuters
·
Aug 08

Entera Bio Ltd expected to post a loss of 11 cents a share - Earnings Preview

Reuters
·
Aug 05

Entera Bio Shares Climb as FDA Backs New Primary Endpoint in Osteoporosis Study

Dow Jones
·
Jul 29

Entera Bio Ltd. Concluded Annual Shareholders Meeting

Reuters
·
Jul 19

OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress

GlobeNewswire
·
Jul 08

Entera Bio Files $100 Million Mixed Shelf

MT Newswires Live
·
May 31

Entera Bio Ltd. Files Initial Statement of Beneficial Ownership for Chief Business Officer Gautam Leslie Velka

Reuters
·
May 21

Entera Bio Q1 EPS $(0.06) Beats $(0.07) Estimate, Sales $42.00K

Benzinga
·
May 10

Press Release: Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

Dow Jones
·
May 10

Entera Bio Ltd expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
May 06

Entera Bio’s EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis - Highlighted as Oral Presentation at WCO-IOF ESCEO

GlobeNewswire
·
Apr 15

Entera Bio Ltd reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Apr 02

Entera Bio Ltd expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
Mar 31

Entera Bio FY 2024 GAAP EPS $(0.25), Sales $181.000K Beat $139.000K Estimate

Benzinga
·
Mar 29